This is a preview of subscription content, log in via an institution to check access.
References
Dandona P, Mathieu C, Phillip M et al (2017) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 5(11):864–876. https://doi.org/10.1016/S2213-8587(17)30308-X
Garg SK, Henry RR, Banks P et al (2017) Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377:2337–2348. https://doi.org/10.1056/NEJMoa1708337
Rosenstock J, Marquard J, Laffel LM et al (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41:2560–2569. https://doi.org/10.2337/dc18-1749
Henry RR, Thakkar P, Tong C et al (2015) Efficacy and Safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38:2258–2265. https://doi.org/10.2337/dc15-1730
Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 10:15. https://doi.org/10.2337/dc18-2316
Acknowledgements
The authors thank all the diabetes specialists who took their time to respond to this survey and acknowledge the support of the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD) to this project.
Funding
This study received no direct funding. Support in the management of data collection was offered by the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Regarding the topic of this work, MS has received research grants from Lexicon and consulting fee from Sanofi Italy; for being part of a speaker’s bureau, RC has received compensation from AstraZeneca Italy, PDB has received compensations from AstraZeneca Italy, Boehringer Ingelheim Italy and Mundipharma Italy and GLP has received compensations from AstraZeneca Italy and Boehringer Ingelheim Italy; FB, CM, AG, MSZ and FPT have no conflict of interests to disclose.
Ethical approval
In this manuscript we report the results of survey of professionals, for which no sensitive or health data were collected from patients and no ethics committee review is required.
Human and animal rights disclosure
This research involved no animals.
Informed consent
For this type of study informed consent of participants was not required by current regulations.
Additional information
Managed by Massimo Porta.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Scavini, M., Bertuzzi, F., Girelli, A. et al. Off-label prescription of SGLT-2 inhibitors to patients with type 1 diabetes: an online survey of diabetes specialists in Italy. Acta Diabetol 56, 1235–1238 (2019). https://doi.org/10.1007/s00592-019-01386-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-019-01386-7